Search Results

Immorna today announced that the first subject has been dosed in the Company’s First-In-Human (FIH) Phase 1 multi-center study of JCXH-105, a self-replicating RNA (srRNA) vaccine being developed for the prevention of Shingles (Herpes Zoster; HZ).

Immorna today announced that the U.S. Food and Drug Administration (FDA) has cleared its investigational new drug (IND) application to conduct a Phase 1 multi-center study of JCXH-105.

Immorna today announced that the U.S. Food and Drug Administration (FDA) has cleared its investigational new drug (IND) application to conduct a Phase 1/2 multi-center study of JCXH-221.

Immorna Biotherapeutics, Inc. (Immorna), a rapidly-expanding biotechnology company developing both self-replicating and conventional mRNA-based therapeutics and vaccines, announced today that the U.S. Food and Drug Administration (FDA) has cleared its investigational new drug (IND) application for JCXH-211, a novel self-replicating mRNA encoding human interleukin (IL)-12 protein.

Immorna Biotherapeutics, Inc announces appointment of Drs. NgocDiep Le, Jeffrey Ulmer, Marcin Bugno, Lan Feng, and Mr. Jeffrey Carey to key roles, strengthening its exiting strong leadership team.

Junshi Biosciences announced that the company has established a joint venture with Immorna, a fast-growing biotechnology company focusing on the process development and optimization of mRNA and delivery vehicles and the research and development of new nucleic acid drugs, to develop and commercialize new drugs for the global market in the fields of cancer, infectious diseases, rare diseases, and other diseases, based on the mRNA technology and other technology platforms.

I-Mab today announced the signing of two new collaborations with emerging biotech companies in China to strengthen its next-generation innovation pipeline.